{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:20:16Z","timestamp":1784262016091,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Daprodustat is a hypoxia\u2010inducible factor\u2010prolyl hydroxylase inhibitor in development for treatment of anemia of chronic kidney disease. We evaluated the role of hepatic impairment on daprodustat pharmacokinetics, pharmacodynamics, and tolerability. Participants with mild (Child\u2010Pugh Class A, score 5\u20126) and moderate (Child\u2010Pugh Class B, score 7\u20129) hepatic impairment and matched healthy controls were administered single 6\u2010mg doses of daprodustat. Exposure parameters were determined for daprodustat and its six metabolites. Comparisons resulted in 1.5\u2010 and 2.0\u2010fold higher daprodustat C<jats:sub>max<\/jats:sub> and area under the curve (AUC) exposures in participants with mild and moderate hepatic impairment, respectively, versus controls; C<jats:sub>max<\/jats:sub> in mild hepatic impairment was comparable to controls. Similarly, aligned with parent drug, unbound daprodustat C<jats:sub>max<\/jats:sub> and AUC exposures increased 1.6\u2010 to 2.3\u2010fold in hepatic\u2010impaired participants versus controls, and metabolite exposures were 1.2\u2010 to 2.0\u2010fold higher in participants with hepatic impairment. Erythropoeitin (EPO) baseline\u2010corrected AUC exposures were between 0.3\u2010fold lower and 2.2\u2010fold higher in matched controls versus hepatic\u2010impaired participants. No serious or study drug\u2010related adverse events were reported. Daprodustat exposure was increased in participants with moderate and mild hepatic impairment compared with matched controls; however, no meaningful differences in EPO were observed and no new safety concerns were identified (ClinicalTrials.gov: NCT03223337).<\/jats:p>","DOI":"10.1002\/cpdd.1090","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T05:46:37Z","timestamp":1648705597000},"page":"562-575","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function"],"prefix":"10.1002","volume":"11","author":[{"given":"Kelly M.","family":"Mahar","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Modeling &amp; Simulation GlaxoSmithKline  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie C.","family":"Shaddinger","sequence":"additional","affiliation":[{"name":"Medicine Delivery Unit GlaxoSmithKline  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandi","family":"Ramanjineyulu","sequence":"additional","affiliation":[{"name":"Biostatistics GlaxoSmithKline  Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Andrews","sequence":"additional","affiliation":[{"name":"Clinical Science &amp; Study Operations GlaxoSmithKline  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Caltabiano","sequence":"additional","affiliation":[{"name":"Medicine Delivery Unit GlaxoSmithKline  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair C.","family":"Lindsay","sequence":"additional","affiliation":[{"name":"Medicine Delivery Unit GlaxoSmithKline  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Cobitz","sequence":"additional","affiliation":[{"name":"Medicine Delivery Unit GlaxoSmithKline  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011111078"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft443"},{"issue":"4","key":"e_1_2_8_4_1","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.09.026"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907845"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065485"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005109"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.295"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.16011219"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1547-z"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy013"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014111139"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy014"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.12.011"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.83"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.327"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz013"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2015.11.057"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623319880445"},{"key":"e_1_2_8_21_1","first-page":"S54","article-title":"Human Metabolism and disposition of daprodustat: a prolyl hydroxylase inhibitor to treat anemia in chronic kidney disease (CKD)","volume":"109","author":"Chen L","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1029"},{"key":"e_1_2_8_23_1","volume-title":"Bioanalytic Method Validation Guidance for Industry","author":"Food and Drug Administration","year":"2018"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i3.1260"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840210121"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0553-z"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520310008340"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1090","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T23:30:43Z","timestamp":1693006243000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/cpdd.1090"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1090","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"assertion":[{"value":"2020-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}